163 related articles for article (PubMed ID: 18398041)
1. MDM2 SNP309 is associated with endometrial cancer risk.
Terry K; McGrath M; Lee IM; Buring J; De Vivo I
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):983-6. PubMed ID: 18398041
[TBL] [Abstract][Full Text] [Related]
2. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
3. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
4. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
[TBL] [Abstract][Full Text] [Related]
5. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
[TBL] [Abstract][Full Text] [Related]
7. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
10. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
11. Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.
Zhao Y; Yang X; Hao X; Pan X; Zhao B; Ma J; Fang J; Zhao M
Tumour Biol; 2014 Aug; 35(8):7555-60. PubMed ID: 24792886
[TBL] [Abstract][Full Text] [Related]
12. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
13. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
[TBL] [Abstract][Full Text] [Related]
14. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
15. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
16. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.
Ashton KA; Proietto A; Otton G; Symonds I; McEvoy M; Attia J; Gilbert M; Hamann U; Scott RJ
Gynecol Oncol; 2009 Apr; 113(1):109-14. PubMed ID: 19193430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
